Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Preclinical Oncology Services (PRECOS), a pre-clinical research and development service with a specific focus on oncology, has signed a service agreement with Janssen Pharma.
Subscribe to our email newsletter
The contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.
PRECOS was launched as a spin-off from the University of Nottingham, UK in August 2010 and it offers patient-relevant models which closely reflect the patient situation for each aspect of cancer progression encompassing pre-cancerous lesions, primary tumours and metastasis.
PRECOS chief scientific officer Sue Watson said that this global contract further strengthens the long term relationship between PRECOS and Janssen and consolidates PRECOS’ evolution from a primarily academic background into an ambitious commercial entity, offering significant scientific expertise and delivering specialist services in the development of new anti-cancer drugs.
Janssen Research & Development Global Oncology Research head Martin Page said that their agreement with PRECOS is a natural extension of their relationship with the University of Nottingham.